Empa Add on to Insulin in Japanese Patient With Type 1 Diabetes Mellitus
Status:
Completed
Trial end date:
2016-10-03
Target enrollment:
Participant gender:
Summary
To assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of once daily oral
doses of empagliflozin in Japanese patients with type 1 diabetes mellitus as adjunctive
therapy to insulin.